生物資訊學領域的合作與授權協議（2019-2026）

生物資訊學領域併購的決定性指標

生物資訊學合作以數據、計算平台和分析能力為驅動力，交易結構體現了對演算法、資料集和整合藥物發現技術的存取。

本報告對生物資訊學領域的 1230 多項合作與許可協議進行了全面系統的分析，清楚地展示了夥伴關係在整個市場中的設計、談判和執行方式，並提供了實證支持。

清楚了解市場標準

本報告將使您對生物資訊交易的實際運作方式有精準的了解，使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以清楚地了解交易條件如何因平台類型、資料存取權限和合作夥伴概況而異。
• 支持實證評估和結構性決策
• 內部討論應基於實際交易數據，而非假設。
• 了解大型公司如何處理交易
• 在資料密集型、技術主導的環境中，可視化合作夥伴行為和迭代交易結構。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，使您能夠詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解生物資訊學夥伴關係中價值、風險和控制權的分配方式至關重要，尤其是在資料所有權、平台存取和整合到藥物發現工作流程中是關鍵考慮因素的情況下。
• 專為實際業務拓展和策略制定而設計。

本報告廣泛用於以下用途：

• 建置和基準測試資料主導和基於平台的交易。
• 在清晰的市場環境下準備談判
• 評估技術合作夥伴和合作機會
• 支援穩健且引人注目的數據驅動型內部策略
• 內容
• 超過 1230 項生物資訊學合作及授權協議。
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 一個可全文搜尋的合約目錄（按公司、平台和應用程式分類）。
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 分析交易趨勢、重大交易和活躍的交易商。
• 可靠的、基於證據的生物資訊交易參考資料。
• 本報告結合全面的交易覆蓋範圍和合約層面的見解，為如何在生物資訊領域建立、談判和評估夥伴關係提供了可靠的、基於證據的指導。

目錄

執行摘要

第1章：引言

第2章：生物資訊學領域的發展趨勢

• 介紹
• 長期生物資訊相關交易
• 最活躍的生物資訊相關人員
• 生物資訊相關交易（按交易類型）
• 生物資訊相關交易（依治療領域分類）
• 生物資訊相關交易（按行業分類）
• 與生物資訊學相關的交易條款和條件

第3章：生物資訊學領域的主要交易

• 介紹
• 生物資訊學領域交易量最高

第4章：生物資訊學領域最活躍的相關人員

• 介紹
• 最活躍的生物資訊相關人員
• 最活躍的生物資訊相關交易公司簡介

第5章：生物資訊合約談判指南

• 介紹
• 生物資訊學合約交易目錄

第6章：生物資訊學中的技術類型交易

• 特價優惠列表
• 交易目錄 - 生物資訊相關交易（依公司分類）(AZ)
• 交易目錄 - 生物資訊相關交易（依交易類型分類）
• 交易目錄 - 按治療領域分類的生物資訊交易
• 交易類型的定義
• 關於這家研究公司
• 當前夥伴關係
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for bioinformatics dealmaking

Bioinformatics partnering is driven by data, computational platforms, and analytical capabilities, with deal structures reflecting access to algorithms, datasets, and integrated discovery technologies.

This report provides a comprehensive and structured analysis of 1230+ bioinformatics collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how bioinformatics deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by platform type, data access, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a data-intensive and technology-driven landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within bioinformatics partnerships, particularly where data ownership, platform access, and integration into discovery workflows are key considerations.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark data-driven and platform-based transactions
• Prepare for negotiations with well-defined market context
• Evaluate technology partners and collaboration opportunities
• Support internal strategy with robust, defensible data
• What's included
• 1230+ bioinformatics collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, platform, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for bioinformatics dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how bioinformatics partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in bioinformatic dealmaking

• 2.1. Introduction
• 2.2. Bioinformatic deals over the years
• 2.3. Most active bioinformatic dealmakers
• 2.4. Bioinformatic deals by deal type
• 2.5. Bioinformatic deals by therapy area
• 2.6. Bioinformatic deals by industry sector
• 2.7. Deal terms for bioinformatic deals
  • 2.7.1 Bioinformatic deals headline values
  • 2.7.2 Bioinformatic deal upfront payments
  • 2.7.3 Bioinformatic deal milestone payments
  • 2.7.4 Bioinformatic royalty rates

Chapter 3 - Leading bioinformatic deals

• 3.1. Introduction
• 3.2. Top bioinformatic deals by value

Chapter 4 - Most active bioinformatic dealmakers

• 4.1. Introduction
• 4.2. Most active bioinformatic dealmakers
• 4.3. Most active bioinformatic deals company profiles

Chapter 5 - Bioinformatic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Bioinformatic contracts dealmaking directory

Chapter 6 - Bioinformatic dealmaking by technology type

• Deal directory
• Deal directory - Bioinformatic deals by company A-Z
• Deal directory - Bioinformatic deals by deal type
• Deal directory - Bioinformatic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Bioinformatic deals since 2019
• Figure 2: Active bioinformatic dealmaking activity
• Figure 3: Bioinformatic deals by deal type since 2019
• Figure 4: Bioinformatic deals by therapy area since 2019
• Figure 5: Bioinformatic deals by industry sector since 2019
• Figure 6: Bioinformatic deals with a headline value
• Figure 7: Bioinformatic deals with an upfront value
• Figure 8: Bioinformatic deals with a milestone value
• Figure 9: Bioinformatic deals with a royalty rate value
• Figure 10: Top bioinformatic deals by value since 2019
• Figure 11: Most active bioinformatic dealmakers
• Figure 12: Bioinformatic deals by technology type since 2019